nach oben

Archives of Virology

Erschienen in:

01.03.2011 | Original Article

Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice

verfasst von: Jian Wu, Fuyan Wang, Fang Fang, Wenjie Zhang, Haiyan Chang, Liyun Zheng, Ze Chen

Erschienen in: Archives of Virology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Vaccination is the preferred strategy for the prevention of influenza virus infection. Both H5N1 subunit and split vaccines have shown poor immunogenicity in clinical trials thus far. Therefore, it is urgent to develop more immunogenic and antigen-sparing H5N1 influenza vaccines as well as safe and effective adjuvants for humans, especially for immunocompromised people such as patients with diabetes mellitus. In this study, the protective effect of an MF59-adjuvanted inactivated whole-virion H5N1 vaccine was investigated in a type 1 diabetic mouse model. Mice (both healthy and diabetic) were immunized with a single dose of the inactivated vaccine, alone or adjuvanted with MF59 or Al(OH)₃. After four weeks, mice were challenged with a lethal dose of H5N1 virus. Antibody responses, survival rates, lung virus titers and body weight changes were tested. The results showed that addition of MF59 or Al(OH)₃ to the vaccine enhanced the antibody responses in both healthy mice and diabetic mice, but the MF59-adjuvanted groups showed higher antibody responses than the Al(OH)₃-adjuvanted groups. The addition of MF59 or Al(OH)₃ to the vaccine led to a conversion of the immune response from a Th1-biased response to an enhanced mixed Th1/Th2 profile. The MF59-adjuvanted inactivated whole-virion H5N1 vaccine provided superior protection in type 1 diabetic mice to either the vaccine alone or the vaccine adjuvanted with Al(OH)₃.

Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P (2008) Cross-protection by MF59-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against a(H3N2) drifted influenza viruses. Vaccine 26:1525-1529

Baldo V, Baldovin T, Floreani A, Carraro A M, Trivello R (2007) MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications. Vaccine 25:3955-3961

Banzhoff A, Nacci P, Podda A (2003) A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: Results from an immunogenicity meta-analysis. Gerontology 49:177-184

Beigel J H, Farrar J, Han A M, Hayden F G, Hyer R, de Jong M D, Lochindarat S, Nguyen T K, Nguyen T H, Tran T H, Nicoll A, Touch S, Yuen K Y (2005) Avian influenza a (H5N1) infection in humans. N Engl J Med 353:1374-1385

Beyer W E, Palache A M, Osterhaus A D (1998) Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: A review and meta-analysis of the literature. Clin Drug Investig 15:1-12

Bresson J L, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Hoschler K, Zambon M C (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367:1657-1664

Bungener L, Geeraedts F, Ter Veer W, Medema J, Wilschut J, Huckriede A (2008) Alum boosts Th2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26:2350-2359

Burke R L, Goldbeck C, Ng P, Stanberry L, Ott G, Van Nest G (1994) The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J Infect Dis 170:1110-1119

Cataldo D M, Van Nest G (1997) The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine 15:1710-1715

10.

Chen QJ, Kuang HM, Wang HD, Fang F, Yang ZD, Zhang ZP, Zhang XE, Chen Z (2009) Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus Genes 38:30-38

11.

Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A, Dowell S F (2005) Human disease from influenza a (H5N1), thailand, 2004. Emerg Infect Dis 11:201-209

12.

Del Giudice G, Hilbert A K, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A (2006) An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 24:3063-3065

13.

Diepersloot R J, Bouter K P, Beyer W E, Hoekstra J B, Masurel N (1987) Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 30:397-401

14.

Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A (2001) Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 17:135-140

15.

Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A (2008) Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi Viruses 2:41-51

16.

Geerlings S E, Hoepelman A I (1999) Immune dysfunction in patients with diabetes mellitus (dm). FEMS Immunol Med Microbiol 26:259-265

17.

Hovden A O, Cox R J, Haaheim L R (2005) Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in Balb/c mice. Scand J Immunol 62:36-44

18.

Huber V C, McKeon R M, Brackin M N, Miller L A, Keating R, Brown S A, Makarova N, Perez D R, Macdonald G H, McCullers J A (2006) Distinct contributions of vaccine-induced immunoglobulin g1 (IgG 1) and IgG 2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981-990

19.

Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G (2008) Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3:e1665

20.

Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Wang X, Wood J, Feng Z, Wang Y, Yin W (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza a (H5N1) vaccine: A phase I randomised controlled trial. Lancet 368:991-997

21.

McLaren C, Verbonitz M W, Daniel S, Grubbs G E, Ennis F A (1977) Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J Infect Dis 136 Suppl:S706-711

22.

Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P (1999) Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 17:99-104

23.

Muller L M, Gorter K J, Hak E, Goudzwaard W L, Schellevis F G, Hoepelman A I, Rutten G E (2005) Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41:281-288

24.

Nicholson K G, Tyrrell D A, Harrison P, Potter C W, Jennings R, Clark A, Schild G C, Wood J M, Yetts R, Seagroatt V, Huggins A, Anderson S G (1979) Clinical studies of monovalent inactivated whole virus and subunit A/Ussr/77 (H1N1) vaccine: Serological responses and clinical reactions. J Biol Stand 7:123-136

25.

Ninomiya A, Imai M, Tashiro M, Odagiri T (2007) Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 25:3554-3560

26.

Ott G, Barchfeld G L, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G (1995) MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm Biotechnol 6:277-296

27.

Pozzilli P, Arduini P, Visalli N, Sutherland J, Pezzella M, Galli C, Corradini S G, Biasio L, Gale E A, Andreani D (1987) Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 30:817-819

28.

Qiu M, Fang F, Chen Y, Wang H, Chen Q, Chang H, Wang F, Zhang R, Chen Z (2006) Protection against avian influenza H9N2 virus challenge by immunization with hemagglutinin- or neuraminidase-expressing DNA in Balb/c mice. Biochem Biophys Res Commun 343:1124-1131

29.

Renegar K B, Small P A, Jr., Boykins L G, Wright P F (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173:1978-1986

30.

Smith S A, Poland G A (2003) Immunization and the prevention of influenza and pneumococcal disease in people with diabetes. Diabetes Care 26 Suppl 1:S126-128

31.

Smith S A, Poland G A (2004) Influenza and pneumococcal immunization in diabetes. Diabetes Care 27 Suppl 1:S111-113

32.

Stephenson I, Nicholson K G, Gluck R, Mischler R, Newman R W, Palache A M, Verlander N Q, Warburton F, Wood J M, Zambon M C (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: Phase I randomised trial. Lancet 362:1959-1966

33.

Szyszko E, Brokstad K, Cox R J, Hovden A O, Madhun A, Haaheim L R (2006) Impact of influenza vaccine formulation with a detailed analysis of the cytokine response. Scand J Immunol 64:467-475

34.

Tamura S I, Asanuma H, Ito Y, Hirabayashi Y, Suzuki Y, Nagamine T, Aizawa C, Kurata T, Oya A (1992) Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine. Eur J Immunol 22:477-481

35.

Traquina P, Morandi M, Contorni M, Van Nest G (1996) MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. J Infect Dis 174:1168-1175

36.

Treanor J J, Campbell J D, Zangwill K M, Rowe T, Wolff M (2006) Safety and immunogenicity of an inactivated subvirion influenza a (H5N1) vaccine. N Engl J Med 354:1343-1351

37.

Treanor J J, Wilkinson B E, Masseoud F, Hu-Primmer J, Battaglia R, O’Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz J M (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737

38.

Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I (2007) Inactivated whole virus influenza a (H5N1) vaccine. Emerg Infect Dis 13:807-808

39.

Valensi J P, Carlson J R, Van Nest G A (1994) Systemic cytokine profiles in Balb/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants. J Immunol 153:4029-4039

40.

van Riel D, Munster V J, de Wit E, Rimmelzwaan G F, Fouchier R A, Osterhaus A D, Kuiken T (2006) H5N1 virus attachment to lower respiratory tract. Science 312:399

41.

Wack A, Baudner B C, Hilbert A K, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, Montomoli E, Del Giudice G, Rappuoli R, O’Hagan D T (2008) Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 26:552-561

42.

WHO. (accessed 06 May 2009.) Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_09_24/en/index.html

43.

WHO. (accessed Aug 17, 2006.) Development and evaluation of influenza pandemic vaccines: Report of who expert meeting. Initiative for vaccine research, global influenza programme. http://www.who.int/vaccine_research/documents/Report%20021105.pdf

44.

WHO. WHO manual on animal influenza diagnosis and surveillance. (http://www.Who.Int/vaccine_research/diseases/influenza/who_manual_on_animal-diagnosis_and_surveillance_2002_5.Pdf), WH0, 2002.

45.

Wright P F, Thompson J, Vaughn W K, Folland D S, Sell S H, Karzon D T (1977) Trials of influenza A/New Jersey/76 virus vaccine in normal children: An overview of age-related antigenicity and reactogenicity. J Infect Dis 136 Suppl:S731-741

46.

Wu J, Zhang F, Fang F, Chang H, Wang F, Yang Z, Sun B, Chen Z (2010) Efficacy of inactivated vaccine against H5N1 influenza virus infection in mice with type 1 diabetes. Vaccine 28:2775-2781

47.

Zheng L, Wang F, Yang Z, Chen J, Chang H, Chen Z (2009) A single immunization with ha DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice. BMC Infect Dis 9:17

48.

Zhu Q, Chang H, Chen Y, Fang F, Xue C, Zhang F, Qiu M, Wang H, Wang B, Chen Z (2005) Protection of inactivated influenza virus vaccine against lethal influenza virus infection in diabetic mice. Biochem Biophys Res Commun 329:87-94

Titel: Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice
verfasst von: Jian Wu
Fuyan Wang
Fang Fang
Wenjie Zhang
Haiyan Chang
Liyun Zheng
Ze Chen
Publikationsdatum: 01.03.2011
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 3/2011
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-010-0860-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Sequence analysis of the replicase gene of ‘sweet potato caulimo-like virus’ suggests that this virus is a distinct member of the genus Cavemovirus

Complete nucleotide sequence of a potato isolate of strain group C of Potato virus Y from 1938

MHV-68 Open Reading Frame 20 is a nonessential gene delaying lung viral clearance

The complete genome sequence of a Passion fruit woodiness virus isolate from Australia determined using deep sequencing, and its relationship to other potyviruses

Complete nucleotide sequence of a new variant of grapevine rupestris stem pitting-associated virus from southern Italy

Sequence analysis of the glycoprotein E gene of varicella-zoster virus strains of clades 1, 3 and 5